Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2019-09-27 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
《公司章程》修正案
Governance Information Classification · 95% confidence The document is a formal announcement regarding amendments to the company's Articles of Association (公司章程). It details specific changes to the company's business scope and mentions the need for shareholder meeting approval and subsequent registration procedures. There is no financial data, no mention of annual or interim reports, earnings, or other financial disclosures. The document is about governance and internal company rules changes, specifically the Articles of Association, which falls under governance information. The document length is short and it is not a report publication announcement or certification. Therefore, the appropriate classification is Governance Information (CGR).
2019-09-27 Chinese
第四届董事会第二十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board meeting of Shenzhen Xinlitai Pharmaceutical Co., Ltd. It includes decisions on participation in a fund, changes to the company's business scope and articles of association, and the appointment of a new deputy general manager. The content focuses on board decisions and management changes, including the appointment of a senior executive with detailed background information. There are no financial statements or quarterly/yearly financial results presented. The document is not a report itself but an official announcement of board resolutions and management changes. Therefore, it fits best under Board/Management Information (MANG). The document length is 2708 characters, which is consistent with a detailed announcement but not a full report.
2019-09-27 Chinese
公司章程（2019年9月）
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (章程) of Shenzhen Salubris Pharmaceuticals Co., Ltd. It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, share transfer, shareholder meetings, and other governance matters. It is a legal and governance document that sets out the internal rules and regulations of the company. There is no indication that this is a financial report, audit report, earnings release, or any other type of financial or regulatory filing. Instead, it fits the description of Governance Information (CGR), which covers the company's internal rules, board structure, and governance practices.
2019-09-27 Chinese
关于参与设立股权投资基金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen Xinlitai Pharmaceutical Co., Ltd. regarding its participation in establishing an equity investment fund. It details the investment overview, parties involved, fund structure, investment purpose, risks, and approvals. The text is a formal disclosure typical of a regulatory announcement about a capital investment or financing activity. It does not contain financial statements, earnings data, or management discussion of financial results. It is not a report like an Annual Report (10-K) or Interim Report (IR), nor is it a call transcript or AGM material. The content focuses on a financing-related transaction (setting up an investment fund and the company's capital commitment). Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (7766 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2019-09-27 Chinese
独立董事关于公司有关事项所发表的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent director's opinion regarding the appointment of a deputy general manager at Shenzhen Xinlitai Pharmaceutical Co., Ltd. It references compliance with company law, stock exchange listing rules, and company articles. The document is a formal opinion letter from independent directors confirming the legitimacy and qualifications of the appointment. It does not contain financial statements, audit results, or detailed financial data. It is not an announcement of voting results or a proxy solicitation. It is a regulatory compliance document related to management appointments but does not announce a change in board or senior management itself. Given the nature and length (746 characters), it is best classified as a Regulatory Filing (RNS), which is the fallback for miscellaneous compliance documents that do not fit other categories.
2019-09-27 Chinese
关于使用自有资金增资诺泰国际有限公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's use of its own funds to increase capital in its wholly-owned subsidiary, including details about the investment amount, board approval, investment purpose, risks, and financial data of the subsidiary. It is a formal disclosure of a capital increase transaction rather than a full financial report or earnings release. The document length is 2406 characters, which is relatively short and focused on a specific financing event. There is no indication of it being a full annual or interim report, audit report, or earnings release. The content fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes through the increase of capital in a subsidiary.
2019-09-02 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.